What is HC Wainwright's Estimate for CRBU FY2026 Earnings?

Key Points

• HC Wainwright has projected that Caribou Biosciences will report FY2026 earnings of ($1.63) per share, slightly better than the consensus estimate of ($1.64) per share.
• Caribou Biosciences recently received an upgrade from Wall Street Zen, moving from a "sell" to a "hold" rating, with three analysts currently rating the stock as a Buy.
• The company's stock opened at $1.86 and has experienced significant price movement over the past year, with a low of $0.66 and a high of $3.00.

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - HC Wainwright issued their FY2026 earnings estimates for Caribou Biosciences in a note issued to investors on Tuesday, September 23rd. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($1.63) per share for the year. The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share.

Separately, Wall Street Zen upgraded Caribou Biosciences from a "sell" rating to a "hold" rating in a research note on Sunday, August 24th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, Caribou Biosciences currently has an average rating of "Buy" and a consensus price target of $6.67.

Caribou Biosciences Price Performance

Shares of CRBU stock opened at $1.86 on Wednesday. The stock's fifty day simple moving average is $1.93 and its 200 day simple moving average is $1.35. Caribou Biosciences has a one year low of $0.66 and a one year high of $3.00. The firm has a market cap of $173.20 million, a price-to-earnings ratio of -1.04 and a beta of 2.54.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.05. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%.The company had revenue of $2.67 million for the quarter, compared to analyst estimates of $1.64 million.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Caribou Biosciences by 4.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 176,654 shares of the company's stock valued at $281,000 after purchasing an additional 8,199 shares during the last quarter. CWM LLC lifted its holdings in Caribou Biosciences by 53.5% in the second quarter. CWM LLC now owns 33,839 shares of the company's stock valued at $43,000 after buying an additional 11,798 shares during the period. Vanguard Personalized Indexing Management LLC boosted its stake in Caribou Biosciences by 69.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 40,813 shares of the company's stock valued at $51,000 after acquiring an additional 16,736 shares during the last quarter. Next Capital Management LLC bought a new position in Caribou Biosciences in the second quarter valued at approximately $25,000. Finally, Nelson Capital Management LLC grew its holdings in Caribou Biosciences by 31.1% during the 1st quarter. Nelson Capital Management LLC now owns 85,020 shares of the company's stock worth $78,000 after acquiring an additional 20,162 shares during the period. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.